Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.40 Insider Own4.53% Shs Outstand98.83M Perf Week-29.55%
Market Cap7.54M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float94.35M Perf Month-1.80%
Income-36.85M PEG- EPS next Q- Inst Own2.32% Short Float4.82% Perf Quarter-54.58%
Sales9.74M P/S0.77 EPS this Y- Inst Trans-9.83% Short Ratio0.31 Perf Half Y-76.33%
Book/sh0.79 P/B0.10 EPS next Y- ROA-48.71% Short Interest4.54M Perf Year-90.22%
Cash/sh0.02 P/C4.49 EPS next 5Y- ROE-76.41% 52W Range0.07 - 0.88 Perf YTD-82.67%
Dividend Est.- P/FCF- EPS past 5Y22.72% ROI-90.33% 52W High-91.38% Beta-0.12
Dividend TTM- Quick Ratio0.26 Sales past 5Y325.62% Gross Margin-21.20% 52W Low9.16% ATR (14)0.02
Dividend Ex-Date- Current Ratio0.38 EPS Y/Y TTM25.12% Oper. Margin-380.10% RSI (14)33.51 Volatility13.61% 24.31%
Employees84 Debt/Eq0.55 Sales Y/Y TTM40.46% Profit Margin-378.23% Recom1.00 Target Price8.00
Option/ShortYes / Yes LT Debt/Eq0.43 EPS Q/Q68.15% Payout- Rel Volume1.15 Prev Close0.10
Sales Surprise- EPS Surprise- Sales Q/Q358.80% EarningsMay 29 BMO Avg Volume14.48M Price0.08
SMA20-32.38% SMA50-46.77% SMA200-76.69% Trades Volume16,627,013 Change-21.34%
Jun-03-24 08:00AM
May-29-24 07:00AM
May-20-24 08:00AM
May-16-24 04:15PM
08:00AM Loading…
May-15-24 08:00AM
May-14-24 01:55PM
May-07-24 08:30AM
Apr-29-24 08:00AM
Apr-23-24 05:27AM
Apr-22-24 05:00PM
Mar-19-24 08:30AM
Mar-14-24 08:30AM
Mar-12-24 05:00PM
12:20AM Loading…
Mar-08-24 12:20AM
Mar-07-24 04:18PM
Feb-06-24 08:00AM
Feb-01-24 08:00AM
Jan-30-24 08:00AM
Jan-25-24 08:30AM
Jan-16-24 08:30AM
Jan-08-24 08:30AM
Jan-03-24 08:30AM
Dec-21-23 08:30AM
Dec-18-23 08:30AM
Dec-12-23 08:30AM
Nov-20-23 04:05PM
Oct-09-23 08:26AM
08:24AM Loading…
Aug-24-23 08:24AM
Aug-14-23 04:05PM
May-19-23 10:46AM
May-15-23 04:05PM
Apr-11-23 08:23AM
Mar-31-23 04:05PM
Dec-12-22 09:02AM
Nov-14-22 04:01PM
Oct-21-22 08:00AM
Aug-23-22 07:30AM
Aug-17-22 10:55AM
Aug-10-22 04:05PM
Jun-13-22 08:00AM
May-18-22 12:48PM
May-16-22 04:44PM
May-10-22 08:00AM
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.